Novo Nordisk seeks FDA nod for oral diabetes pill

Novo Nordisk seeks FDA nod for oral diabetes pill

Source: 
Drug Delivery Business News
snippet: 

Novo Nordisk (NYSE:NVO) said this week that it submitted applications to the FDA for its oral formulation of semaglutide, a once-daily glucagon-like peptide-1 receptor agonist therapy.